Author

Irvin T. Garza

The University of Texas Southwestern Medical CenterORCID 0000-0002-2152-9072Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Neuroscience· 2 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 3 Research Focus:drug response / drug discovery· 1 Organism:non-human primate· 1

Frequent Co-Authors

Rachel M. BaileyiD· 3 shared K. L. Knight· 2 shared Sydni K. Holmes· 2 shared Ashwani Kumar· 1 shared Brina SnyderiD· 1 shared Chao XingiD· 1 shared Chao XingiD· 1 shared Cynthia B. Trygg· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersNeuroscience

Rachel M. BaileyORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

A minimally modified AAV9 variant (AAV9fyhr) for enhanced CNS gene delivery by intra-CSF administration.

Irvin T. Garza, Vijayashree Ramesh, Yuhui Hu, Matthew Rioux, Mehmet Takar, Harrison Higgs, Erik Allen Lykken, Rachel Adams, Peter Kunach, Daniel Kieffer, Cynthia B. Trygg, Jeanne M. Fisher‐Perkins, Ashwani Kumar, Łukasz A. Joachimiak, Rachel M. Bailey, , Steven James Gray

This paper describes a novel AAV9 variant, AAV9fyhr, that improves CNS gene delivery while minimizing peripheral tissue tropism through targeted amino acid modifications.

bioRxiv · Oct 9, 2026 · PreprintBioengineering

Preclinical Development of a Vectorized Artificial miRNA Gene Therapy for Tauopathies

Irvin T. Garza, Brina Snyder, Sydni K. Holmes, Katherine M. Pearce, K. L. Knight, Rachel M. Bailey

This paper develops a gene therapy using artificial miRNA delivered via adeno-associated virus to reduce tau in a mouse model of tauopathy, showing efficacy even at late disease stages.

bioRxiv · Oct 12, 2025 · PreprintNeuroscience

AAV-mediated gene therapy for SLC13A5 citrate transporter disorder rescues epileptic and metabolic phenotypes

Lauren E. Bailey, Morgan K. Schackmuth, Raegan M. Adams, Irvin T. Garza, K. L. Knight, Sydni K. Holmes, Meghan M. Eller, MinJae Lee, Rachel M. Bailey

This study shows that AAV-mediated gene therapy in SLC13A5-deficient mice reduces extracellular citrate, normalizes electrophysiologic and sleep issues, and improves seizure resistance.

bioRxiv · Jul 3, 2025 · PreprintNeuroscience